Ultrasound screening of fetuses at increased risk for Down syndrome: How many missed diagnoses?

Aaron Caughey, Deirdre J. Lyell, A. Eugene Washington, Roy A. Filly, Mary E. Norton

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: To determine the number of Down syndrome (DS) fetuses identified, amniocenteses performed, and procedure-related losses incurred when second-trimester ultrasound is used to screen high-risk patients in order to determine who should undergo an amniocentesis. Methods: A decision analytic model was designed for women at increased risk for a DS fetus due to either advanced maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein (MSAFP) screening test, also known as a triple screen (+triple) test. The model compared: (1) the current standard of offering all at-risk women amniocentesis to (2) a policy of performing amniocentesis only when sonographic markers of DS are seen on ultrasound. Baseline assumptions included a sensitivity of 60.6% for targeted ultrasound and a screen-positive rate of 16.2%. Results: If targeted ultrasound is used to determine whether high-risk patients should undergo amniocentesis, 56% (3933/7025) of all DS fetuses are missed. The diagnosis of DS is missed most frequently among women at highest risk for DS (AMA and +triple). In this subgroup of patients, there are 3152 DS fetuses in the second trimester, of which 2815 (89%) are identified by triple screen test. When an ultrasound screen is added, only 1709 (54%) of DS fetuses will be identified. Conclusion: Substantially fewer DS fetuses will be detected when targeted ultrasound is used as a screen among already identified high-risk patients.

Original languageEnglish (US)
Pages (from-to)22-27
Number of pages6
JournalPrenatal Diagnosis
Volume26
Issue number1
DOIs
StatePublished - Jan 2006
Externally publishedYes

Fingerprint

Down Syndrome
Fetus
Amniocentesis
Maternal Age
Second Pregnancy Trimester
alpha-Fetoproteins
Mothers
Serum

Keywords

  • Down syndrome
  • Prenatal diagnosis
  • Ultrasound

ASJC Scopus subject areas

  • Genetics(clinical)
  • Obstetrics and Gynecology

Cite this

Ultrasound screening of fetuses at increased risk for Down syndrome : How many missed diagnoses? / Caughey, Aaron; Lyell, Deirdre J.; Washington, A. Eugene; Filly, Roy A.; Norton, Mary E.

In: Prenatal Diagnosis, Vol. 26, No. 1, 01.2006, p. 22-27.

Research output: Contribution to journalArticle

Caughey, Aaron ; Lyell, Deirdre J. ; Washington, A. Eugene ; Filly, Roy A. ; Norton, Mary E. / Ultrasound screening of fetuses at increased risk for Down syndrome : How many missed diagnoses?. In: Prenatal Diagnosis. 2006 ; Vol. 26, No. 1. pp. 22-27.
@article{cabd1667e08346d8818bca37364eea4a,
title = "Ultrasound screening of fetuses at increased risk for Down syndrome: How many missed diagnoses?",
abstract = "Objective: To determine the number of Down syndrome (DS) fetuses identified, amniocenteses performed, and procedure-related losses incurred when second-trimester ultrasound is used to screen high-risk patients in order to determine who should undergo an amniocentesis. Methods: A decision analytic model was designed for women at increased risk for a DS fetus due to either advanced maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein (MSAFP) screening test, also known as a triple screen (+triple) test. The model compared: (1) the current standard of offering all at-risk women amniocentesis to (2) a policy of performing amniocentesis only when sonographic markers of DS are seen on ultrasound. Baseline assumptions included a sensitivity of 60.6{\%} for targeted ultrasound and a screen-positive rate of 16.2{\%}. Results: If targeted ultrasound is used to determine whether high-risk patients should undergo amniocentesis, 56{\%} (3933/7025) of all DS fetuses are missed. The diagnosis of DS is missed most frequently among women at highest risk for DS (AMA and +triple). In this subgroup of patients, there are 3152 DS fetuses in the second trimester, of which 2815 (89{\%}) are identified by triple screen test. When an ultrasound screen is added, only 1709 (54{\%}) of DS fetuses will be identified. Conclusion: Substantially fewer DS fetuses will be detected when targeted ultrasound is used as a screen among already identified high-risk patients.",
keywords = "Down syndrome, Prenatal diagnosis, Ultrasound",
author = "Aaron Caughey and Lyell, {Deirdre J.} and Washington, {A. Eugene} and Filly, {Roy A.} and Norton, {Mary E.}",
year = "2006",
month = "1",
doi = "10.1002/pd.1319",
language = "English (US)",
volume = "26",
pages = "22--27",
journal = "Prenatal Diagnosis",
issn = "0197-3851",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Ultrasound screening of fetuses at increased risk for Down syndrome

T2 - How many missed diagnoses?

AU - Caughey, Aaron

AU - Lyell, Deirdre J.

AU - Washington, A. Eugene

AU - Filly, Roy A.

AU - Norton, Mary E.

PY - 2006/1

Y1 - 2006/1

N2 - Objective: To determine the number of Down syndrome (DS) fetuses identified, amniocenteses performed, and procedure-related losses incurred when second-trimester ultrasound is used to screen high-risk patients in order to determine who should undergo an amniocentesis. Methods: A decision analytic model was designed for women at increased risk for a DS fetus due to either advanced maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein (MSAFP) screening test, also known as a triple screen (+triple) test. The model compared: (1) the current standard of offering all at-risk women amniocentesis to (2) a policy of performing amniocentesis only when sonographic markers of DS are seen on ultrasound. Baseline assumptions included a sensitivity of 60.6% for targeted ultrasound and a screen-positive rate of 16.2%. Results: If targeted ultrasound is used to determine whether high-risk patients should undergo amniocentesis, 56% (3933/7025) of all DS fetuses are missed. The diagnosis of DS is missed most frequently among women at highest risk for DS (AMA and +triple). In this subgroup of patients, there are 3152 DS fetuses in the second trimester, of which 2815 (89%) are identified by triple screen test. When an ultrasound screen is added, only 1709 (54%) of DS fetuses will be identified. Conclusion: Substantially fewer DS fetuses will be detected when targeted ultrasound is used as a screen among already identified high-risk patients.

AB - Objective: To determine the number of Down syndrome (DS) fetuses identified, amniocenteses performed, and procedure-related losses incurred when second-trimester ultrasound is used to screen high-risk patients in order to determine who should undergo an amniocentesis. Methods: A decision analytic model was designed for women at increased risk for a DS fetus due to either advanced maternal age (AMA) or a positive expanded maternal serum alpha fetoprotein (MSAFP) screening test, also known as a triple screen (+triple) test. The model compared: (1) the current standard of offering all at-risk women amniocentesis to (2) a policy of performing amniocentesis only when sonographic markers of DS are seen on ultrasound. Baseline assumptions included a sensitivity of 60.6% for targeted ultrasound and a screen-positive rate of 16.2%. Results: If targeted ultrasound is used to determine whether high-risk patients should undergo amniocentesis, 56% (3933/7025) of all DS fetuses are missed. The diagnosis of DS is missed most frequently among women at highest risk for DS (AMA and +triple). In this subgroup of patients, there are 3152 DS fetuses in the second trimester, of which 2815 (89%) are identified by triple screen test. When an ultrasound screen is added, only 1709 (54%) of DS fetuses will be identified. Conclusion: Substantially fewer DS fetuses will be detected when targeted ultrasound is used as a screen among already identified high-risk patients.

KW - Down syndrome

KW - Prenatal diagnosis

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=31944449425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31944449425&partnerID=8YFLogxK

U2 - 10.1002/pd.1319

DO - 10.1002/pd.1319

M3 - Article

C2 - 16378329

AN - SCOPUS:31944449425

VL - 26

SP - 22

EP - 27

JO - Prenatal Diagnosis

JF - Prenatal Diagnosis

SN - 0197-3851

IS - 1

ER -